38. Revisiting the Great Debate JAKs vs TNFs
ACR on Air
00:00
Jax Inhibitors in Rheumatoid Arthritis
In 2021, the FDA updated their black box warning after results from a large randomized safety clinical trial that showed an increased risk of heart attack, stroke, cancer, blood clots, and death when Tophasetinib was compared against TNF inhibitors in patients with rheumatoid arthritis. We wanted to revisit, have these clinical trial findings and FDA warnings changed your mind about the use of Jax inhibitors in people with rhearatoid arthritis. Well, that's a long question and a long answer. If you'll give me a second. That's a great thing about podcasting. And we still got non-inferiority, but those definitions were quite strict.
Transcript
Play full episode
